Trial Profile
A single-center, double-blinded, randomized, placebo-controlled, single ascending dose study with food effect crossover and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and hemostatic profile of VE-01902
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2019
Price :
$35
*
At a glance
- Drugs VE-1902 (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions; First in man; Pharmacodynamics
- Acronyms VE-01902-REPLACE-Ia-001
- Sponsors VCR1
- 30 Aug 2019 Planned number of patients changed from 142 to 134.
- 13 Feb 2019 Planned initiation date changed from 15 Oct 2018 to 8 Jan 2019.
- 13 Feb 2019 Status changed from not yet recruiting to recruiting.